Our resource hub to discover reports, policy papers and other forms of informative content
For the second year in a row,
we saw considerable growth
in the number of claimants
with an 8.5% increase, making
it the main driver of overall
cost. This increase in claimants
was balanced by a low single
digit increase in the cost per
claimants of 2.7%. Read the full report.
This study examines the contribution of the Canadian research and development (R&D) pharmaceutical sector on the Canadian economy in 2021. […]
In many areas of high unmet patient need, early access to new medicines through clinical trials are the only option for Canadian patients. There are over 3,000 ongoing clinical trials in Canada which provide significant value to patients. Early access to innovative treatments improves health outcomes, increases quality of life, and gives hope to patients and their loved ones. Clinical trials also provide value to our healthcare system, research ecosystem, and economy.
Annual cost growth in Canada’s private drug benefit market is driven by increased utilization and chronic disease drugs, with an increase in claimants post‑pandemic.
Read the full report.
Informative content to keep you up to date on the most pressing issues facing our industry.
